Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 16/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 16/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16543578 | 0.92 | PDGFRB (0.42) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL16537959 | 0.91 | PDGFRB (0.41) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL16537463 | 0.91 | PDGFRB (0.41) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL16536686 | 0.90 | PDGFRB (0.41) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL16537576 | 0.87 | PDGFRB (0.50) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL16537282 | 0.87 | PDGFRB (0.50) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL5143388 | 0.83 | PDGFRB (0.40) | PDGFRBPDGFRAALDH1A1GLAGAA | |
| SCHEMBL8163880 | 0.80 | PDGFRB (0.52) | PDGFRBPDGFRA | |
| SCHEMBL22798874 | 0.76 | SLC22A12 (0.39) | ALDH1A1MAPT | |
| SCHEMBL14437924 | 0.76 | PDGFRB (0.63) | PDGFRBPDGFRAALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | PDGFRB 228/4885PDGFRA 193/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.